Evidence map›Paper›PMID 26559904›Full record

ReviewAlimentary pharmacology & therapeutics2016

Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders.

K Gottlieb, V Wacher, J Sliman, M Pimentel

Open access · bronzeAbstract readReview
In one paragraph

Review in Alimentary pharmacology & therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Methanogenic archaea in the human gastrointestinal tract.Nature reviews. Gastroenterology & hepatology · 2022
    Review
  11. Article
  12. Review
  13. Review
  14. Lovastatin as a supplement to mitigate rumen methanogenesis: an overview.Journal of animal science and biotechnology · 2021
    Review
  15. Review
  16. The host-associated archaeome.Nature reviews. Microbiology · 2020
    Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

K GottliebSynthetic Biologics, Inc., Rockville, MD, USA.
V WacherSynthetic Biologics, Inc., Rockville, MD, USA.
J SlimanSynthetic Biologics, Inc., Rockville, MD, USA.
M PimentelGastroenterology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Synthetic Biologics (United States) · USCedars-Sinai Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundObservational studies show a strong association between delayed intestinal transit and the production of methane. Experimental data suggest a direct inhibitory activity of methane on the colonic and ileal smooth muscle and a possible role for methane as a gasotransmitter. Archaea are the only confirmed biological sources of methane in nature and Methanobrevibacter smithii is the predominant methanogen in the human intestine.

aimTo review the biosynthesis and composition of archaeal cell membranes, archaeal methanogenesis and the mechanism of action of statins in this context.

methodsNarrative review of the literature.

resultsStatins can inhibit archaeal cell membrane biosynthesis without affecting bacterial numbers as demonstrated in livestock and humans. This opens the possibility of a therapeutic intervention that targets a specific aetiological factor of constipation while protecting the intestinal microbiome. While it is generally believed that statins inhibit methane production via their effect on cell membrane biosynthesis, mediated by inhibition of the HMG-CoA reductase, there is accumulating evidence for an alternative or additional mechanism of action where statins inhibit methanogenesis directly. It appears that this other mechanism may predominate when the lactone form of statins, particularly lovastatin lactone, is administered.

conclusionsClinical development appears promising. A phase 2 clinical trial is currently in progress that evaluates the effect of lovastatin lactone on methanogenesis and symptoms in patients with irritable bowel syndrome with constipation. The review concludes with an outlook for the future and subsequent work that needs to be done.

Indexed as

ArchaeaConstipationHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIrritable Bowel SyndromeMaleMethaneHydroxymethylglutaryl-CoA Reductase InhibitorsMethane

Identifiers

PMID26559904
PMCPMC4737270
OpenAlexW2099125766

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.